[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 760
51. Tsigkou A, Marrelli D, Reis FM, Luisi S, Silva-Filho AL, Roviello F, Triginelli SA, Petraglia F: Total inhibin is a potential serum marker for epithelial ovarian cancer. J Clin Endocrinol Metab; 2007 Jul;92(7):2526-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total inhibin is a potential serum marker for epithelial ovarian cancer.
  • CONTEXT: Total inhibin is the sum of precursors, subunits, and mature molecules of inhibin, which the normal ovary nearly stops to produce after menopause, whereas ovarian tumors still release.
  • OBJECTIVE: The aim of the present study was to evaluate whether the serum concentration of total inhibin has the sensitivity/specificity characteristics to become a diagnostic test for epithelial ovarian cancer in postmenopausal women.
  • 1) epithelial ovarian cancer, stage II-III (n = 89);.
  • 2) benign ovarian tumors (n = 25);.
  • In the group of women with epithelial ovarian cancer, blood specimens were also collected after surgical removal of the tumor.
  • RESULTS: Women with epithelial ovarian cancers showed serum total inhibin levels significantly higher than those with benign tumor or with nonovarian tumors or controls (P < 0.001).
  • When total inhibin was combined with CA-125, all cases of serous and mucinous tumors were detected, and the overall sensitivity for epithelial ovarian cancers was 99% at 95% specificity.
  • CONCLUSIONS: The present data show that total inhibin is a sensitive and specific marker of epithelial ovarian cancers in postmenopausal women.
  • Total inhibin may therefore be combined with CA-125 for noninvasive diagnosis of epithelial ovarian cancer and may also be a useful serum marker to monitor disease-free intervals.
  • [MeSH-major] Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / diagnosis. Biomarkers, Tumor / blood. Immunoenzyme Techniques / methods. Inhibins / blood. Ovarian Neoplasms / blood. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / diagnosis. Aged. Aged, 80 and over. CA-125 Antigen / blood. Cross-Sectional Studies. Epithelium / pathology. Female. Humans. Middle Aged. ROC Curve

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17473066.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 57285-09-3 / Inhibins
  •  go-up   go-down


52. Kusuda T, Shigemasa K, Arihiro K, Fujii T, Nagai N, Ohama K: Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. Oncol Rep; 2005 Jun;13(6):1153-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
  • The aim of the present study was to examine mRNA expression levels of Th1 (TNF-alpha , IFN-gamma, and IL-12p40) and Th2 (IL-6 and IL-10) cytokines for any association with clinicopathological characteristics of epithelial ovarian cancer. mRNA was isolated, and cDNA prepared from 40 samples of epithelial ovarian cancers.
  • Tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) expression levels were significantly higher in serous adenocarcinoma than in non-serous adenocarcinoma (p<0.05), but with no difference between individual cytokine mRNA expression levels and clinical stage or histological grade.
  • Log-rank testing showed that high TNF-alpha mRNA expression (p=0.033) and the diameter of largest residual lesion at initial surgery (p=0.012) significantly correlate with longer survival in advanced stage (II/III/IV) ovarian carcinomas.
  • In examining all combinations of Th1/Th2 expression values, the most significant association was between high IFN-gamma.IL-12p40/IL-6 expression levels and better prognosis in advanced stage (II/III/IV) ovarian carcinomas (p=0.004).
  • In conclusion, Th1 and Th2 cytokines might play an important role in regulating the immune reaction in epithelial ovarian cancer cells.
  • IFN-gamma.IL-12p40/IL-6 expression may be a useful prognostic molecular marker for patients with advanced ovarian cancer.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Th1 Cells / metabolism. Th2 Cells / metabolism
  • [MeSH-minor] Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. DNA, Complementary / genetics. DNA, Complementary / metabolism. Female. Humans. Interferon-gamma / genetics. Interferon-gamma / metabolism. Interleukin-10 / genetics. Interleukin-10 / metabolism. Interleukin-12 / genetics. Interleukin-12 / metabolism. Interleukin-12 Subunit p40. Interleukin-6 / genetics. Interleukin-6 / metabolism. Ovary / metabolism. Ovary / pathology. Prognosis. Protein Subunits / genetics. Protein Subunits / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Necrosis Factor-alpha / genetics. Tumor Necrosis Factor-alpha / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870936.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Interleukin-12 Subunit p40; 0 / Interleukin-6; 0 / Protein Subunits; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 187348-17-0 / Interleukin-12; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


53. Tada E, Toyomura K, Nakamura H, Sasaki H, Saito T, Kaneko M, Okuma Y, Murayama T: Activation of ceramidase and ceramide kinase by vanadate via a tyrosine kinase-mediated pathway. J Pharmacol Sci; 2010;114(4):420-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also we found that 1) treatment of NBD-ceramide-labeled cells (human lung adenocarcinoma A549 cells and Chinese hamster ovary cells) with Na(3)VO(4) increased the amount of NBD-C1P formed within 30 min, 2) the treatment increased production of NBD-caproic acid, a counterpart of sphingosine, by ceramidase within 2 h, 3) expression of ceramide kinase enhanced the Na(3)VO(4)-induced formation of NBD-C1P, and tyrosine kinase inhibitors (herbimycin and genistein) decreased the response, 4) the production of NBD-caproic acid in A549 cells was inhibited by genistein, and 5) the responses for 2 h after Na(3)VO(4) treatment were accompanied by a decrease in the production of NBD-sphingomyelin, not a loss of NBD-ceramide.

  • National BioResource Project. culture/stock collections - NBRP resources .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21127389.001).
  • [ISSN] 1347-8648
  • [Journal-full-title] Journal of pharmacological sciences
  • [ISO-abbreviation] J. Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Ceramides; 0 / ceramide 1-phosphate; 3WHH0066W5 / Vanadates; EC 2.7.1.- / Phosphotransferases (Alcohol Group Acceptor); EC 2.7.1.138 / ceramide kinase; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 3.5.1.23 / Ceramidases; NGZ37HRE42 / Sphingosine
  •  go-up   go-down


5
Advertisement
4. McCluggage WG, Young RH: Paraganglioma of the ovary: report of three cases of a rare ovarian neoplasm, including two exhibiting inhibin positivity. Am J Surg Pathol; 2006 May;30(5):600-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraganglioma of the ovary: report of three cases of a rare ovarian neoplasm, including two exhibiting inhibin positivity.
  • Paraganglioma is one of the rarest neoplasms to involve the ovary, whether primary or metastatic, with only two previous reports.
  • Two tumors involved the left ovary and one the right ovary; they ranged from 8 to 22 cm, were solid, and were tan, brown, or yellow.
  • One tumor was confined to the ovary; in the second case, there were tumor deposits on the posterior surface of the uterus and the contralateral ovary; in the other case, there was peri-aortic lymph node involvement and peritoneal deposits.
  • Although metastatic spread from an undetected primary outside the ovary cannot be totally excluded for the 2 cases with extraovarian disease, we think that the neoplasms most likely represent primary ovarian paragangliomas.
  • Because various neoplasms in the sex cord-stromal and steroid categories are likely to enter into the differential diagnosis, inhibin and calretinin positivity represents a significant potential diagnostic pitfall.
  • The differential is broad and may include many other ovarian tumors, particularly those with an oxyphilic cell type.
  • Possible theories of histogenesis of primary ovarian paraganglioma include an origin from extra-adrenal paraganglia in the region of the ovary or unidirectional differentiation within a teratoma.
  • [MeSH-major] Inhibins / metabolism. Ovarian Neoplasms / pathology. Paraganglioma, Extra-Adrenal / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Microscopy, Electron, Transmission. Middle Aged. S100 Proteins. Sex Cord-Gonadal Stromal Tumors / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16699314.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / S100 Proteins; 57285-09-3 / Inhibins
  •  go-up   go-down


55. Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, Mabuchi K, Kodama K: Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res; 2007 Jul;168(1):1-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid cancer incidence in atomic bomb survivors: 1958-1998.
  • The analyses were based on 17,448 first primary cancers (including non-melanoma skin cancer) diagnosed from 1958 through 1998 among 105,427 cohort members with individual dose estimates who were alive and not known to have had cancer prior to 1958.
  • Radiation-associated relative risks and excess rates were considered for all solid cancers as a group, for 19 specific cancer sites or groups of sites, and for five histology groups.
  • It was estimated that, at age 70 after exposure at age 30, solid cancer rates increase by about 35% per Gy (90% CI 28%; 43%) for men and 58% per Gy (43%; 69%) for women.
  • Despite the decline in the ERR with attained age, excess absolute rates appeared to increase throughout the study period, providing further evidence that radiation-associated increases in cancer rates persist throughout life regardless of age at exposure.
  • Significant radiation-associated increases in risk were seen for most sites, including oral cavity, esophagus, stomach, colon, liver, lung, non-melanoma skin, breast, ovary, bladder, nervous system and thyroid.
  • However, there was emerging evidence from the present data that exposure as a child may increase risks of cancer of the body of the uterus.
  • Elevated risks were seen for all of the five broadly classified histological groups considered, including squamous cell carcinoma, adenocarcinoma, other epithelial cancers, sarcomas and other non-epithelial cancers.
  • Although the data were limited, there was a significant radiation-associated increase in the risk of cancer occurring in adolescence and young adulthood.
  • In view of the persisting increase in solid cancer risks, the LSS should continue to provide important new information on radiation exposure and solid cancer risks for at least another 15 to 20 years.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722996.001).
  • [ISSN] 0033-7587
  • [Journal-full-title] Radiation research
  • [ISO-abbreviation] Radiat. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CP / N01-CP-31021; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


56. Christie DR, Shaikh FM, Lucas JA 4th, Lucas JA 3rd, Bellis SL: ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function. J Ovarian Res; 2008 Oct 01;1(1):3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function.
  • BACKGROUND: Ovarian adenocarcinoma is not generally discovered in patients until there has been widespread intraperitoneal dissemination, which is why ovarian cancer is the deadliest gynecologic malignancy.
  • Our laboratory has previously shown that the Golgi glycosyltransferase, ST6Gal-I, mediates the hypersialylation of beta1 integrins in colon adenocarcinoma, which leads to a more metastatic tumor cell phenotype.
  • Interestingly, ST6Gal-I mRNA is known to be upregulated in metastatic ovarian cancer, therefore the goal of the present study was to determine whether ST6Gal-I confers a similarly aggressive phenotype to ovarian tumor cells.
  • METHODS: Three ovarian carcinoma cell lines were screened for ST6Gal-I expression, and two of these, PA-1 and SKOV3, were found to produce ST6Gal-I protein.
  • CONCLUSION: ST6Gal-I mediated sialylation of beta1 integrins in ovarian cancer cells may contribute to peritoneal metastasis by altering tumor cell adhesion and migration through extracellular matrix.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2005;69(5):436-44 [16319516.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):67-75 [11206841.001]
  • [Cites] Clin Exp Metastasis. 2004;21(8):685-97 [16035613.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4645-52 [15930282.001]
  • [Cites] Glycobiology. 1999 Oct;9(10):1003-8 [10521536.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2253-9 [9605774.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):362-7 [10366461.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5722-7 [10318951.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1525-37 [10329605.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):243-7 [10188726.001]
  • [Cites] Oncology. 1999;56(2):89-96 [9949292.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4066-70 [9751611.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1997;254(9-10):437-41 [9438113.001]
  • [Cites] Biochim Biophys Acta. 1998 Jan 8;1379(1):23-8 [9468328.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4249-56 [9331085.001]
  • [Cites] FEBS Lett. 1997 Jun 16;409(3):347-50 [9224687.001]
  • [Cites] Int J Cancer. 1996 Sep 17;67(6):826-30 [8824555.001]
  • [Cites] J Biol Chem. 1994 Apr 8;269(14):10637-43 [8144653.001]
  • [Cites] Eur J Biochem. 1993 Jan 15;211(1-2):135-40 [7678804.001]
  • [Cites] Glycobiology. 1992 Feb;2(1):49-56 [1550989.001]
  • [Cites] J Biol Chem. 1990 Oct 15;265(29):17849-53 [2211665.001]
  • [Cites] Br J Cancer. 1991 Oct;64(4):617-20 [1911209.001]
  • [Cites] Eur J Biochem. 2004 Sep;271(18):3623-34 [15355339.001]
  • [Cites] Biochim Biophys Acta. 2004 May 27;1663(1-2):52-60 [15157607.001]
  • [Cites] Oncogene. 2003 Oct 16;22(46):7137-45 [14562042.001]
  • [Cites] Hybridoma. 2000 Aug;19(4):281-6 [11001400.001]
  • [Cites] Mol Cell Biol Res Commun. 2000 Jan;3(1):48-52 [10683317.001]
  • [Cites] Glycobiology. 2007 Dec;17(12):1344-56 [17884841.001]
  • [Cites] Lab Invest. 2007 Sep;87(9):851-7 [17632542.001]
  • [Cites] J Cell Biol. 2006 Mar 27;172(7):973-81 [16567498.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):369-75 [16428474.001]
  • [Cites] World J Gastroenterol. 2005 Nov 14;11(42):6701-6 [16425369.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):395-401 [12798701.001]
  • [Cites] Clin Exp Metastasis. 2003;20(2):143-52 [12705635.001]
  • [Cites] Med Res Rev. 2003 Jan;23(1):32-47 [12424752.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):32830-6 [12091385.001]
  • [Cites] Exp Cell Res. 2002 May 15;276(1):101-10 [11978012.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2071-80 [11733357.001]
  • [Cites] Biochim Biophys Acta. 2001 May 31;1536(2-3):148-60 [11406350.001]
  • [Cites] Glycoconj J. 2000 Oct;17(10):669-76 [11425186.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):631-9 [16112178.001]
  • (PMID = 19014651.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA084248
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2584051
  •  go-up   go-down


57. Wamunyokoli FW, Bonome T, Lee JY, Feltmate CM, Welch WR, Radonovich M, Pise-Masison C, Brady J, Hao K, Berkowitz RS, Mok S, Birrer MJ: Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin Cancer Res; 2006 Feb 1;12(3 Pt 1):690-700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance.
  • PURPOSE: To elucidate the molecular mechanisms contributing to the unique clinicopathologic characteristics of mucinous ovarian carcinoma, global gene expression profiling of mucinous ovarian tumors was carried out.
  • Hierarchical clustering and binary tree prediction analysis were used to determine the relationships among mucinous specimens and a series of previously profiled microdissected serous tumors and normal ovarian surface epithelium.
  • RESULTS: Comparison of the gene profiles between mucinous tumors and normal ovarian epithelial cells identified 1,599, 2,916, and 1,765 differentially expressed in genes in the cystadenomas, LMP tumors, and adenocarcinomas, respectively.
  • Furthermore, the cystadenomas coexpressed a subset of genes that were differentially regulated in LMP and adenocarcinoma specimens compared with normal ovarian surface epithelium.
  • PathwayAssist highlighted pathways with expression of genes involved in drug resistance in both LMP and adenocarcinoma samples.
  • CONCLUSIONS: These data provide a useful basis for understanding the molecular events leading to the development and progression of mucinous ovarian cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology
  • [MeSH-minor] Cluster Analysis. Decision Trees. Diagnosis, Differential. Female. Humans. Oligonucleotide Array Sequence Analysis / methods. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16467078.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA165009; United States / NCI NIH HHS / CA / R33CA103595; United States / Intramural NIH HHS / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


58. Saito N, Hatori T, Murata N, Shibuya K, Mitsuda A, Hasegawa C, Akima M, Ikawa M, Nonaka H: A case of concomitant occurrence of struma ovarii and malignant transformation of cystic teratoma. Int J Surg Pathol; 2007 Jul;15(3):318-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 77-year-old woman received a total abdominal hysterectomy and bilateral salpingo-oophorectomy because of a tumor in the left ovary.
  • The tumorous lesion of the cyst wall revealed a poorly differentiated adenocarcinoma.
  • The authors diagnosed that struma ovarii and other parats coexisted as a poorly differentiated adenocarcinoma that had arisen from a mature ovarian cystic teratoma.
  • As for the identification of the origin of adenocarcinomas arising from mature ovarian cystic teratomas, more cases need to be identified and investigated.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Ovarian Neoplasms / pathology. Struma Ovarii / pathology. Teratoma / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Keratin-7 / genetics. Keratin-7 / metabolism. Maximum Tolerated Dose

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17652549.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-7
  •  go-up   go-down


59. Devalapally H, Duan Z, Seiden MV, Amiji MM: Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int J Cancer; 2007 Oct 15;121(8):1830-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer.
  • Subcutaneous sensitive (wild-type) and multidrug resistant (MDR-1 positive) SKOV-3 human ovarian adenocarcinoma xenografts were established in female Nu/Nu mice.
  • The results of this study show that combination of PTX and CER in biodegradable polymeric nanoparticles can serve as a very effective therapeutic strategy to overcome drug resistance in ovarian cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Ceramides / administration & dosage. Drug Resistance, Neoplasm. Nanoparticles. Ovarian Neoplasms / drug therapy. Paclitaxel / administration & dosage. Polyesters

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17557285.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA119617
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biocompatible Materials; 0 / Ceramides; 0 / N-(alpha-hydroxyoctadecanoyl)phytosphingosine; 0 / Polyesters; 0 / polyethylene oxide-polycaprolactone copolymer; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


60. Bolat F, Gumurdulu D, Erkanli S, Kayaselcuk F, Zeren H, Ali Vardar M, Kuscu E: Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma. Pathol Res Pract; 2008;204(6):379-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human ovarian carcinoma.
  • Few studies have compared maspin with VEGF in ovarian carcinoma.
  • Therefore, we investigated the expression and correlation of maspin, VEGFA, VEGFC, and VEGFD with the tumorigenesis of the ovary and clinicopathologic variables.
  • Using immunohistochemistry, we examined maspin, VEGFA, VEGFC, and VEGFD expression in 60 ovarian carcinoma tissues (35 serous papillary carcinomas, 18 endometrioid carcinomas, and 7 primary ovarian mucinous carcinomas).
  • Maspin, VEGFC, and VEGFD are expressed in ovarian tumors with a poor prognostic parameters, and seem to play a role in ovarian cancer angiogenesis, progression, and lymph node metastases.
  • Our results indicate that in contrast to most other carcinomas, maspin expression is directly associated with the biological aggressiveness of ovarian carcinoma.
  • These results may offer new insights regarding the role of maspin in ovarian cancer and might also affect the diagnosis and treatment strategies.
  • [MeSH-major] Adenocarcinoma / metabolism. Ovarian Neoplasms / metabolism. Serpins / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor C / metabolism. Vascular Endothelial Growth Factor D / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Female. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343598.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SERPIN-B5; 0 / Serpins; 0 / VEGFA protein, human; 0 / VEGFC protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 0 / Vascular Endothelial Growth Factor D
  •  go-up   go-down


61. Yu KJ, Lee HE, Ho HC, Lee JC, Chang JW, Hong HS, Yang CH: Carcinoma erysipelatoides from squamous cell carcinoma of unknown origin. Int J Clin Pract; 2005 Sep;59(9):1104-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is frequently observed in patients with breast carcinoma as well as adenocarcinoma of pancreas, rectum, lung, ovary and parotid gland.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115190.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 13
  •  go-up   go-down


62. Stuckey A, Dizon D, Scalia Wilbur J, Kent J, Tejada-Berges T, Gass J, Legare R: Clinical characteristics and choices regarding risk-reducing surgery in BRCA mutation carriers. Gynecol Obstet Invest; 2010;69(4):270-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: BRCA mutation carriers have a high lifetime risk of developing breast and ovarian malignancies.
  • They were more likely to be a BRCA2 mutation carrier, parous, married, employed, and had a prior history of breast cancer.
  • Pathology was typically benign; however, 15% showed ductal carcinoma in situ of the breast, 8% reported infiltrating ductal carcinoma of the breast, 3% was adenocarcinoma of the fallopian tube, and 3% was adenocarcinoma of the ovary.
  • [MeSH-major] BRCA1 Protein / genetics. BRCA2 Protein / genetics. Breast Neoplasms / prevention & control. Mutation. Ovarian Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 S. Karger AG, Basel.
  • (PMID = 20090358.001).
  • [ISSN] 1423-002X
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BLID protein, human; 0 / BRCA1 Protein; 0 / BRCA1 protein, human; 0 / BRCA2 Protein; 0 / BRCA2 protein, human
  •  go-up   go-down


63. Mabuchi S, Kawase C, Altomare DA, Morishige K, Hayashi M, Sawada K, Ito K, Terai Y, Nishio Y, Klein-Szanto AJ, Burger RA, Ohmichi M, Testa JR, Kimura T: Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol Cancer Ther; 2010 Aug;9(8):2411-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.
  • This study examines the role of vascular endothelial growth factor (VEGF) as a therapeutic target in clear cell carcinoma (CCC) of the ovary, which has been regarded as a chemoresistant histologic subtype.
  • Immunohistochemical analysis using tissue microarrays of 98 primary ovarian cancers revealed that VEGF was strongly expressed both in early-stage and advanced-stage CCC of the ovary.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 AACR.
  • [Cites] Gynecol Oncol. 2007 May;105(2):404-8 [17292461.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2408-13 [17363557.001]
  • [Cites] Semin Oncol. 2007 Apr;34(2 Suppl 2):S1-15 [17512352.001]
  • [Cites] J Clin Oncol. 2007 Jul 10;25(20):2894-901 [17617520.001]
  • [Cites] Gynecol Oncol. 2007 Aug;106(2):311-7 [17532031.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3621-7 [17704411.001]
  • [Cites] Cancer Lett. 2007 Nov 8;257(1):73-8 [17686575.001]
  • [Cites] Exp Oncol. 2007 Sep;29(3):197-202 [18004244.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5165-71 [18024863.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5180-6 [18024865.001]
  • [Cites] J Clin Oncol. 2008 Jan 1;26(1):76-82 [18165643.001]
  • [Cites] Cancer Sci. 2008 Apr;99(4):653-8 [18377417.001]
  • [Cites] Gynecol Oncol. 2008 Sep;110(3):336-44 [18639330.001]
  • [Cites] Clin Cancer Res. 2008 Dec 1;14(23):7781-9 [19047105.001]
  • [Cites] J Natl Cancer Inst. 2009 Jun 16;101(12):846-7 [19509354.001]
  • [Cites] Clin Cancer Res. 2009 Sep 1;15(17):5404-13 [19690197.001]
  • [Cites] Cancer Treat Rev. 2009 Nov;35(7):608-15 [19665848.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2448-54 [12114452.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2295-309 [12466143.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1948-56 [12932675.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3194-200 [12860964.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):513-7 [14675669.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):23477-85 [15026414.001]
  • [Cites] Nat Med. 2004 Jun;10(6):594-601 [15156201.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5853-7 [15208673.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):643-9 [15350353.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):16-22 [15385105.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Hum Pathol. 1970 Mar;1(1):73-98 [4330995.001]
  • [Cites] Cancer Res. 1987 Jan 15;47(2):414-8 [3539322.001]
  • [Cites] J Surg Oncol. 1996 Feb;61(2):138-42 [8606546.001]
  • [Cites] Br J Cancer. 1997;76(9):1221-7 [9365173.001]
  • [Cites] Am J Pathol. 1998 Oct;153(4):1249-56 [9777956.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):178-87 [9921991.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7418-26 [15534119.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6422-30 [16166416.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1545-51 [16884363.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1098-106 [17317817.001]
  • [Cites] Mol Cancer Ther. 2007 May;6(5):1517-25 [17513600.001]
  • (PMID = 20663925.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA83638; United States / NCI NIH HHS / CA / P30 CA006927-409041; United States / NCI NIH HHS / CA / R01 CA077429; United States / NCI NIH HHS / CA / CA006927-409041; United States / NCI NIH HHS / CA / CA083638-100003; United States / NCI NIH HHS / CA / CA077429-11; United States / NCI NIH HHS / CA / P30 CA006927-46; United States / NCI NIH HHS / CA / P50 CA083638; United States / NCI NIH HHS / CA / CA77429; United States / NCI NIH HHS / CA / P30 CA006927; United States / NCI NIH HHS / CA / R01 CA077429-11; United States / NCI NIH HHS / CA / P50 CA083638-100003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factors; 2S9ZZM9Q9V / Bevacizumab; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS231507; NLM/ PMC2941981
  •  go-up   go-down


64. Watanabe Y, Tsuchiya H, Sakabe T, Matsuoka S, Akechi Y, Fujimoto Y, Yamane K, Ikeda R, Nishio R, Terabayashi K, Ishii K, Gonda K, Matsumi Y, Ashla AA, Okamoto H, Takubo K, Tomita A, Hoshikawa Y, Kurimasa A, Itamochi H, Harada T, Terakawa N, Shiota G: CD437 induces apoptosis in ovarian adenocarcinoma cells via ER stress signaling. Biochem Biophys Res Commun; 2008 Feb 15;366(3):840-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD437 induces apoptosis in ovarian adenocarcinoma cells via ER stress signaling.
  • A synthetic retinoid, CD437, has been shown to exert potent anti-tumor activity against various types of cancer cell lines, regardless of their sensitivities to natural retinoids.
  • We herein demonstrate that CD437 induces endoplasmic reticulum (ER) stress, including the up-regulation of CHOP, BIP and GADD34 mRNA through ER stress transducer (PERK and IRE1alpha) activation in an ovarian adenocarcinoma cell line, SKOV3.
  • It was also shown that CD437 induced the CHOP and GADD34 expressions in another four ovarian adenocarcinoma cell lines, indicating that CD437 functions as an ER stress inducer in these cell lines.
  • These results suggest that ER stress plays an important role in the mechanism by which CD437 induces apoptosis in ovarian adenocarcinoma cells.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptosis / drug effects. Endoplasmic Reticulum / metabolism. Ovarian Neoplasms / metabolism. Retinoids / administration & dosage. Signal Transduction / drug effects

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18082618.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CD 437; 0 / Retinoids
  •  go-up   go-down


65. Whitworth MK, Backen AC, Clamp AR, Wilson G, McVey R, Friedl A, Rapraeger AC, David G, McGown A, Slade RJ, Gallagher JT, Jayson GC: Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium. Clin Cancer Res; 2005 Jun 15;11(12):4282-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium.
  • We have investigated the relationship among heparan sulfate, FGF-2, and the signal-transducing receptors in human, advanced-stage, serous ovarian adenocarcinoma.
  • This may be taken as a surrogate marker for the distribution of biologically active heparan sulfate and was distributed predominantly in endothelial cells and stroma but was absent from adenocarcinoma cells.
  • The data suggest that the entire extracellular signaling apparatus, consisting of FGF-2, biologically active heparan sulfate, and FGFRs capable of responding to FGF-2, is present in ovarian cancer endothelium, thereby highlighting the cytokine and its cognate receptor as potential targets for the antiangiogenic treatment of this disease.
  • [MeSH-major] Endothelium / pathology. Fibroblast Growth Factor 2 / metabolism. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15958608.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Receptors, Fibroblast Growth Factor; 0 / Sulfates; 103107-01-3 / Fibroblast Growth Factor 2; 9050-30-0 / Heparitin Sulfate; EC 2.7.10.1 / FGFR1 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


66. García-Galvis OF, Cabrera-Ozoria C, Fernández JA, Stolnicu S, Nogales FF: Malignant Müllerian mixed tumor of the ovary associated with yolk sac tumor, neuroepithelial and trophoblastic differentiation (teratoid carcinosarcoma). Int J Gynecol Pathol; 2008 Oct;27(4):515-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant Müllerian mixed tumor of the ovary associated with yolk sac tumor, neuroepithelial and trophoblastic differentiation (teratoid carcinosarcoma).
  • This paper reports a unique stage IV complex ovarian carcinosarcoma in a 69-year patient that had malignant mixed müllerian epithelial and mesenchymal components and also other malignant differentiation such as neuroectodermal (small cell, neuroendocrine, neuroglial, neuronal, and melanocytic) and endodermal (yolk sac tumor) tissues and trophoblastic cells.
  • It was different from a teratoma as it coexisted with, and possibly originated from, a somatic tumor, namely a characteristic endometrioid adenocarcinoma.
  • [MeSH-major] Carcinosarcoma / pathology. Endodermal Sinus Tumor / pathology. Mixed Tumor, Mullerian / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753971.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Zhao C, Florea A, Austin RM: Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with Papanicolaou test findings of atypical glandular cells. Arch Pathol Lab Med; 2010 Jan;134(1):103-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the 75 cases with hrHPV+ AGC results, 13 (17.3%) had cervical intraepithelial neoplasia grades 2/3, 10 (13.3%) had adenocarcinoma in situ, and 3 (4.0%) had cervical invasive adenocarcinoma, whereas for 234 women with hrHPV(-) results, 1 (0.4%) had cervical intraepithelial neoplasia grades 2/3, 1 (0.4%) had adenocarcinoma in situ, 1 each (0.4%) had cervical adenocarcinoma and ovarian carcinoma, and 8 (3.4%) had endometrial carcinoma.
  • CONCLUSIONS: Positive hrHPV AGC results were most strongly associated with cervical intraepithelial neoplasia grades 2/3 and adenocarcinoma in situ in women younger than 50 years.
  • Positive hrHPV AGC results were also present in all 3 cases of invasive cervical adenocarcinoma in women younger than 50 years.
  • Of note, hrHPV(-) AGC results were present in 10 of 13 carcinomas (76.9%) detected after AGC Pap tests, all in women 40 years or older with endometrial adenocarcinomas (n = 8), ovarian carcinoma (n = 1), and cervical adenosquamous carcinoma in a woman (n = 1) in her 50s.
  • Testing for hrHPV after AGC Pap testing was most helpful in the detection of cervical intraepithelial neoplasia grades 2/3, adenocarcinoma in situ, and invasive cervical adenocarcinomas in women younger than 50 years.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. DNA, Viral. Papanicolaou Test. Papillomaviridae / genetics. Uterine Cervical Neoplasms / pathology. Vaginal Smears
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Carcinoma in Situ / virology. Endometrial Neoplasms / pathology. Endometrial Neoplasms / virology. Female. Humans. Middle Aged. Ovarian Neoplasms / pathology. Ovarian Neoplasms / virology. Retrospective Studies. Risk Factors. Sensitivity and Specificity. Young Adult


68. Naegel AJ, Maiss J, Hahn EG, Harsch IA: [Massive ascites of unknown origin. Ovarian tumor]. Med Klin (Munich); 2005 Jan 15;100(1):73-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Massive ascites of unknown origin. Ovarian tumor].
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Ascites / etiology. Ovarian Neoplasms / diagnosis. Precancerous Conditions / diagnosis. Tomography, X-Ray Computed. Ultrasonography
  • [MeSH-minor] Aged. Female. Humans. Neoplasm Invasiveness. Ovary / pathology

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15654547.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


69. Zhang J, Li YL, Zhou CY, Hu YT, Chen HZ: Expression of octamer-4 in serous and mucinous ovarian carcinoma. J Clin Pathol; 2010 Oct;63(10):879-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of octamer-4 in serous and mucinous ovarian carcinoma.
  • AIMS: To assess the expression of Oct4 in epithelial ovarian tumours.
  • METHODS: Expression of Oct4 was evaluated by immunohistochemistry in 460 cases of various epithelial ovarian lesions as well as 35 cases of normal fallopian tube epithelium.
  • RESULTS: Oct4 expression was significantly increased from normal epithelium (both ovarian epithelium and fallopian tube epithelium) to benign and borderline cystadenoma to carcinoma in the serous lesion subgroup.
  • Oct4 overexpression was associated with more advanced FIGO stage and higher histological grade in serous adenocarcinoma.
  • Conversely, Oct4 expression did not differ among mucinous lesions or correlate with clinicopathological parameters in patients with mucinous adenocarcinoma.
  • CONCLUSION: Results suggest that Oct4 expression may contribute to the initiation, promotion and progression of serous ovarian carcinoma; it might be a useful biomarker for the diagnosis and outcome prediction of serous ovarian carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cystadenoma / metabolism. Octamer Transcription Factor-3 / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Disease Progression. Epithelium / metabolism. Fallopian Tubes / metabolism. Female. Humans. Neoplasm Proteins / metabolism. Neoplasm Staging. Ovary / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876318.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Octamer Transcription Factor-3; 0 / POU5F1 protein, human
  •  go-up   go-down


70. Mazziotta RM, Borczuk AC, Powell CA, Mansukhani M: CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall. Appl Immunohistochem Mol Morphol; 2005 Mar;13(1):55-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Paraffin-embedded sections of various adenocarcinomas (13 colonic, 11 mucinous ovarian, 5 serous ovarian, 8 pancreatic, 6 ampullary, 12 gastric, 5 esophageal, 10 endometrial, 29 breast, and 55 lung) and 29 additional lung carcinomas (nonadenocarcinomas) were immunostained with antibodies to CDX2 protein, cytokeratin 7 (CK7), and cytokeratin 20 (CK20).
  • All colorectal and most ovarian mucinous carcinomas were strongly and diffusely immunoreactive for CDX2.
  • All breast, nonmucinous ovarian, and most endometrial and pancreatic adenocarcinomas showed no immunoreactivity for CDX2.
  • The authors conclude that CDX2 is a relatively specific marker for tumors with intestinal differentiation, with the caveat that its expression can be seen in primary large cell and adenocarcinomas of the lung and mucinous carcinomas of the ovary.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Appl Immunohistochem Mol Morphol. 2006 Jun;14(2):249-50 [16785799.001]
  • (PMID = 15722794.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins
  •  go-up   go-down


71. Gontier E, Wartski M, Guinebretiere JM, Alberini JL: 18F-FDG PET/CT in a patient with lymph node metastasis from ovarian adenocarcinoma. AJR Am J Roentgenol; 2006 Sep;187(3):W285-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET/CT in a patient with lymph node metastasis from ovarian adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Lymphatic Metastasis / radionuclide imaging. Ovarian Neoplasms / radionuclide imaging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16928906.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


72. Manjanatha MG, Shelton S, Bishop ME, Lyn-Cook LE, Aidoo A: Dietary effects of soy isoflavones daidzein and genistein on 7,12-dimethylbenz[a]anthracene-induced mammary mutagenesis and carcinogenesis in ovariectomized Big Blue transgenic rats. Carcinogenesis; 2006 Dec;27(12):2555-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DMBA exposure, however, induced significant increases in the lacI MFs in the mammary of both OVX and ovary intact (INT) rats and Hprt MFs in spleen lymphocytes (P<or=0.01).
  • Although DMBA treatment did not induce mammary tumors in the OVX rats, adenoma and adenocarcinoma were detected in the mammary glands of INT rats.

  • Hazardous Substances Data Bank. GENISTEIN .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RepublishedFrom] Carcinogenesis. 2006 Oct;27(10):1970-9 [16709578.001]
  • (PMID = 17127718.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Corrected and Republished Article; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoflavones; 0 / Phytoestrogens; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 6287WC5J2L / daidzein; DH2M523P0H / Genistein
  •  go-up   go-down


73. Salla C, Chatzipantelis P, Konstantinou P, Karoumpalis I, Pantazopoulou A, Dappola V: Endoscopic ultrasound-guided fine-needle aspiration cytology diagnosis of solid pseudopapillary tumor of the pancreas: a case report and literature review. World J Gastroenterol; 2007 Oct 14;13(38):5158-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic ultrasound-guided fine-needle aspiration cytology diagnosis of solid pseudopapillary tumor of the pancreas: a case report and literature review.
  • Clinical laboratory examinations revealed polycystic ovary syndrome, splenomegaly and low serum amylase and carcinoembryonic antigen (CEA) levels.
  • Biopsy confirmed the above cytologic diagnosis.
  • EUS-guided FNA diagnosis of SPTP is accurate.
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / pathology. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / pathology. Adolescent. Biopsy, Fine-Needle / methods. Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / pathology. Diagnosis, Differential. Endosonography / methods. Female. Humans. Pancreas / pathology. Pancreas / ultrasonography

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17876886.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 59
  • [Other-IDs] NLM/ PMC4434650
  •  go-up   go-down


74. Sato KT, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, Nemcek AA Jr, Barakat O, Benson A 3rd, Mandal R, Talamonti M, Wong CY, Miller FH, Newman SB, Shaw JM, Thurston KG, Omary RA, Salem R: Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival. Radiology; 2008 May;247(2):507-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary sites (origins) included colon, breast, neuroendocrine, pancreas, lung, cholangiocarcinoma, melanoma, renal, esophageal, ovary, adenocarcinoma of unknown primary, lymphoma, gastric, duodenal, bladder, angiosarcoma, squamous cell carcinoma, thyroid, adrenal, and parotid.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2008.
  • (PMID = 18349311.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00532740
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Yttrium Radioisotopes
  •  go-up   go-down


75. Nishimura N, Hachisuga T, Nabeshima K, Kawarabayashi T: Synchronous endometrial and ovarian carcinomas: analysis of genetic relationship of the tumors. Int J Oncol; 2005 Dec;27(6):1519-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous endometrial and ovarian carcinomas: analysis of genetic relationship of the tumors.
  • Simultaneous carcinomas of the endometrium and ovary may represent a diagnostic dilemma and the clinical management of such cases may be problematic.
  • In this study, in addition to the clinicopatho-logic classification, we assessed tumor cell clonality in 13 cases with synchronous endometrial and ovarian endometrioid adenocarcinomas using PCR-based microsatellite analysis of microdissected archival tissues for loss of heterozygosity (LOH) and microsatellite instability (MSI).
  • All paired endometrial and ovarian tumors demonstrated either MSI or/and LOH except for 1 case, and therefore the microsatellite analysis was informative in 92.3% of the cases.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Loss of Heterozygosity. Microsatellite Repeats / genetics. Middle Aged. Neoplasm Metastasis / genetics. Neoplasm Metastasis / pathology. Neoplasms, Multiple Primary / genetics. Neoplasms, Multiple Primary / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273207.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


76. Roncati L, Barbolini G, Ghirardini G, Rivasi F: Mature solid teratoma of the fallopian tube mimicking metastasis of endometrial adenocarcinoma: a case report. Int J Surg Pathol; 2010 Dec;18(6):561-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature solid teratoma of the fallopian tube mimicking metastasis of endometrial adenocarcinoma: a case report.
  • This mass was noted on CT scan and considered metastatic in nature since following a bioptical diagnosis of endometrial adenocarcinoma.
  • Hysterectomy and bilateral salpingectomy and ovariectomy were performed and a second minor mature solid teratoma was discovered inside the right ovary.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Teratoma / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282291.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Sughayer MA, Zakarneh L, Abu-Shakra R: Collision metastasis of breast and ovarian adenocarcinoma in axillary lymph nodes: a case report and review of the literature. Pathol Oncol Res; 2009 Sep;15(3):423-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision metastasis of breast and ovarian adenocarcinoma in axillary lymph nodes: a case report and review of the literature.
  • Despite their accepted clinical and genetic association, the incidence of synchronous breast and ovarian carcinoma is rare.
  • Moreover, collision metastasis from both breast and ovarian carcinomas to the same lymph node, to our knowledge has never been reported.
  • Review of the literature revealed eleven cases of metastatic malignant tumors colliding in the same lymph node, none of which had both ovarian and breast carcinoma.
  • One month later the patient was found to have malignant ascites, omental carcinomatosis and an ovarian mass.
  • Histology and immunohistochemistry revealed high grade serous papillary adenocarcinoma.
  • When surgery was done to treat the breast tumor some of the axillary lymph nodes revealed metastases from the breast primary, others metastases from the ovarian primary and one had both tumors in a collision phenomenon.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Lymphatic Metastasis / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1996 Feb;20(2):245-50 [8554115.001]
  • [Cites] Am J Clin Pathol. 1983 Aug;80(2):228-30 [6349326.001]
  • [Cites] Pathol Int. 1996 Oct;46(10):787-90 [8916150.001]
  • [Cites] Int J Urol. 1997 Mar;4(2):222-4 [9179702.001]
  • [Cites] Dis Colon Rectum. 2005 Feb;48(2):384-9 [15812588.001]
  • [Cites] Science. 1994 Oct 7;266(5182):66-71 [7545954.001]
  • [Cites] Arch Pathol Lab Med. 2004 Mar;128(3):318-20 [14987155.001]
  • [Cites] Int Urol Nephrol. 1995;27(6):743-5 [8725040.001]
  • [Cites] Science. 1994 Sep 30;265(5181):2088-90 [8091231.001]
  • [Cites] Arch Pathol Lab Med. 2001 Oct;125(10):1354-7 [11570915.001]
  • [Cites] J Pathol. 1969 Jan;97(1):143-5 [5783628.001]
  • [Cites] Surg Radiol Anat. 1993;15(2):119-23 [7690160.001]
  • (PMID = 19067238.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Carrier Proteins; 0 / Glycoproteins; 0 / PIP protein, human
  • [Number-of-references] 12
  •  go-up   go-down


78. Kato N, Takeda J, Fukase M, Motoyama T: Alternate mucoid and hyalinized stroma in clear cell carcinoma of the ovary: manifestation of serial stromal remodeling. Mod Pathol; 2010 Jun;23(6):881-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alternate mucoid and hyalinized stroma in clear cell carcinoma of the ovary: manifestation of serial stromal remodeling.
  • The stroma in ovarian clear cell carcinoma often shows alternate mucoid and hyalinized change.
  • We examined 60 ovarian clear cell carcinomas for the distribution and nature of the mucoid stroma.
  • For comparison, 125 other surface epithelial ovarian tumors were examined.
  • The spherule-like mucoid stroma and hyalinized stroma are considered complementary diagnostic signatures of ovarian clear cell carcinoma.
  • [MeSH-major] Carcinoma / metabolism. Extracellular Matrix / metabolism. Hyaluronic Acid / metabolism. Mucins / metabolism. Ovarian Neoplasms / metabolism. Stromal Cells / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Animals. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Mice. Mice, Inbred BALB C. Mice, Nude. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305617.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


79. O'Hara SP, Lin JJ: Accumulation of tropomyosin isoform 5 at the infection sites of host cells during Cryptosporidium invasion. Parasitol Res; 2006 Jun;99(1):45-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we use in vitro cultured cell lines, human ileocecal adenocarcinoma HCT-8 and Chinese hamster ovary (CHO), and an in vivo mouse model to investigate the roles of tropomyosin isoforms in Cryptosporidium invasion.

  • MedlinePlus Health Information. consumer health - Cryptosporidiosis.
  • COS Scholar Universe. author profiles.
  • eagle-i research resources. PMID 16479376 (Special Collections) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Parasitol Res. 2002 May;88(5):412-20 [12049457.001]
  • [Cites] Bioessays. 1991 Sep;13(9):429-37 [1796905.001]
  • [Cites] Int Rev Cytol. 1997;170:1-38 [9002235.001]
  • [Cites] J Protozool. 1992 Sep-Oct;39(5):539-44 [1387896.001]
  • [Cites] Nature. 2003 Apr 17;422(6933):775-81 [12700772.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Hum Pathol. 1991 Dec;22(12):1215-24 [1748428.001]
  • [Cites] J Cell Biol. 1995 May;129(3):697-708 [7730405.001]
  • [Cites] J Cell Sci. 2004 Jul 15;117(Pt 16):3593-604 [15226374.001]
  • [Cites] Clin Immunol. 2001 Dec;101(3):289-95 [11726221.001]
  • [Cites] Korean J Parasitol. 1998 Dec;36(4):227-34 [9868887.001]
  • [Cites] Histochem Cell Biol. 2002 Dec;118(6):491-500 [12483314.001]
  • [Cites] Mol Cell Neurosci. 1995 Oct;6(5):397-412 [8581312.001]
  • [Cites] J Cell Sci. 1996 May;109 ( Pt 5):981-9 [8743945.001]
  • [Cites] Mol Cell Neurosci. 1997;8(6):439-54 [9143561.001]
  • [Cites] Cell Motil Cytoskeleton. 2000 Nov;47(3):189-208 [11056521.001]
  • [Cites] J Biol Chem. 2004 Jul 23;279(30):31671-8 [15133042.001]
  • [Cites] Infect Immun. 2000 Apr;68(4):2315-22 [10722635.001]
  • [Cites] Clin Exp Immunol. 1999 Nov;118(2):219-27 [10540182.001]
  • [Cites] J Cell Biol. 1988 Aug;107(2):563-72 [3047141.001]
  • [Cites] Cell Motil Cytoskeleton. 2000 Feb;45(2):121-32 [10658208.001]
  • [Cites] Mol Biol Cell. 2003 Mar;14(3):1002-16 [12631719.001]
  • [Cites] Hybridoma. 1985 Fall;4(3):223-42 [3899907.001]
  • [Cites] Clin Exp Immunol. 2000 Sep;121(3):466-71 [10971512.001]
  • [Cites] Gastroenterology. 1998 May;114(5):912-22 [9558279.001]
  • [Cites] Infect Immun. 1999 Feb;67(2):844-52 [9916099.001]
  • [Cites] J Biol Chem. 1989 May 5;264(13):7490-7 [2540194.001]
  • [Cites] J Cell Sci. 2002 Dec 1;115(Pt 23):4649-60 [12415009.001]
  • [Cites] Parasitol Res. 2004 Mar;92(4):317-27 [14727189.001]
  • [Cites] J Cell Biol. 1994 Apr;125(2):359-68 [8163552.001]
  • [Cites] Infect Immun. 2001 Sep;69(9):5940-2 [11500478.001]
  • [Cites] Curr Biol. 2001 Aug 21;11(16):1300-4 [11525747.001]
  • [Cites] J Cell Biol. 1989 Sep;109(3):1141-52 [2670955.001]
  • [Cites] Cell Motil Cytoskeleton. 1998;40(4):393-407 [9712268.001]
  • [Cites] Gastroenterology. 1986 Mar;90(3):583-94 [3943690.001]
  • [Cites] Curr Opin Cell Biol. 1994 Feb;6(1):96-104 [8167032.001]
  • [Cites] Cell Motil Cytoskeleton. 1993;26(3):248-61 [8293480.001]
  • [Cites] Annu Rev Cell Dev Biol. 1998;14:339-72 [9891787.001]
  • [Cites] Eur J Cell Biol. 1985 Sep;38(2):245-53 [3899645.001]
  • [Cites] AIDS. 1998 Dec 24;12(18):2459-66 [9875584.001]
  • [Cites] J Biol Chem. 1999 Apr 16;274(16):10743-50 [10196146.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(6):2318-23 [14993271.001]
  • [Cites] Eur J Cell Biol. 1999 Nov;78(11):794-801 [10604656.001]
  • (PMID = 16479376.001).
  • [ISSN] 0932-0113
  • [Journal-full-title] Parasitology research
  • [ISO-abbreviation] Parasitol. Res.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD18577
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Protein Isoforms; 0 / Protozoan Proteins; 0 / TPM3 protein, human; 0 / Tropomyosin
  •  go-up   go-down


80. Moschos SJ, Mo YY: Role of SUMO/Ubc9 in DNA damage repair and tumorigenesis. J Mol Histol; 2006 Sep;37(5-7):309-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent reports indicate that Ubc9, the single SUMO E2 enzyme catalyzing the conjugation of SUMO to target proteins, is overexpressed in certain tumors, such as lung adenocarcinoma, ovarian carcinoma and melanoma, suggestive of its clinic significance.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2005 Sep 12;579(22):5007-12 [16122737.001]
  • [Cites] J Urol. 2006 Feb;175(2):739-43 [16407042.001]
  • [Cites] Oncogene. 2003 Aug 14;22(34):5348-57 [12917636.001]
  • [Cites] FEBS Lett. 2003 Jul 10;546(2-3):374-8 [12832072.001]
  • [Cites] Nature. 1995 Jan 5;373(6509):78-81 [7800043.001]
  • [Cites] FEBS Lett. 2004 Aug 27;573(1-3):15-8 [15327968.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jan;6(1):44-55 [15688066.001]
  • [Cites] Genomics. 1996 Oct 15;37(2):183-6 [8921390.001]
  • [Cites] Mol Cell. 2004 May 21;14 (4):491-500 [15149598.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1127-38 [11948124.001]
  • [Cites] J Proteome Res. 2004 Nov-Dec;3(6):1191-200 [15595728.001]
  • [Cites] J Cell Biol. 2005 Dec 19;171(6):947-54 [16344309.001]
  • [Cites] J Biol Chem. 2002 Jan 25;277(4):2958-64 [11709553.001]
  • [Cites] Neoplasia. 2000 May-Jun;2(3):208-25 [10935507.001]
  • [Cites] Nature. 2003 Sep 11;425(6954):188-91 [12968183.001]
  • [Cites] Mutat Res. 2005 Sep 4;577(1-2):275-83 [15922366.001]
  • [Cites] J Biol Chem. 2005 Jun 24;280(25):23566-75 [15817450.001]
  • [Cites] Mol Cell. 2005 Sep 16;19(6):817-28 [16168376.001]
  • [Cites] J Biol Chem. 2005 Feb 18;280(7):5611-21 [15569683.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40389-95 [11384992.001]
  • [Cites] Mol Cell. 2005 Apr 1;18(1):1-12 [15808504.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2899-908 [15838523.001]
  • [Cites] Chem Res Toxicol. 2004 Dec;17 (12 ):1706-15 [15606148.001]
  • [Cites] Trends Biochem Sci. 2003 Jun;28(6):321-8 [12826404.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13225-30 [14578449.001]
  • [Cites] Exp Cell Res. 2002 Nov 1;280(2):212-21 [12413887.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(16):7021-32 [16055714.001]
  • [Cites] Expert Opin Ther Targets. 2005 Dec;9(6):1203-16 [16300471.001]
  • [Cites] J Cell Biol. 2003 Nov 10;163(3):477-87 [14597774.001]
  • [Cites] Mol Cell. 2006 Mar 17;21(6):837-48 [16543152.001]
  • [Cites] Nucleic Acids Res. 2000 Mar 1;28(5):1145-53 [10666456.001]
  • [Cites] Gene. 1997 May 6;190(2):287-96 [9197546.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):5004-12 [15561718.001]
  • [Cites] FEBS Lett. 2005 Jun 20;579(16):3369-75 [15922331.001]
  • [Cites] Oncogene. 2005 Apr 14;24(16):2677-83 [15735760.001]
  • [Cites] Mol Cell. 2005 Jul 1;19(1):123-33 [15989970.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2793-8 [15087395.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(5):1786-94 [16478998.001]
  • [Cites] Dev Biol. 2005 Dec 1;288(1):60-72 [16248995.001]
  • [Cites] Annu Rev Biochem. 2004;73:39-85 [15189136.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2872-7 [11867732.001]
  • [Cites] Nature. 2002 Sep 12;419(6903):135-41 [12226657.001]
  • [Cites] EMBO J. 2002 Mar 15;21(6):1456-64 [11889051.001]
  • [Cites] Dev Cell. 2005 Dec;9(6):769-79 [16326389.001]
  • [Cites] Cancer Cell. 2004 May;5(5):465-75 [15144954.001]
  • [Cites] Hum Mol Genet. 2005 May 15;14(10):1351-65 [15829507.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4046-51 [10759568.001]
  • [Cites] Mol Biol Cell. 2006 Apr;17 (4):1643-51 [16421255.001]
  • [Cites] Chembiochem. 2005 Oct;6(10 ):1735-43 [16142820.001]
  • [Cites] Cell. 2003 Nov 26;115(5):565-76 [14651848.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):4102-10 [15590687.001]
  • [Cites] Mol Cell. 2003 Apr;11(4):1043-54 [12718889.001]
  • [Cites] Exp Hematol. 2003 Jun;31(6):446-54 [12829019.001]
  • [Cites] Nature. 2005 Jul 21;436(7049):428-33 [15931174.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50157-66 [15355988.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4755-63 [11709548.001]
  • [Cites] Nucleic Acids Res. 2005 Jul 19;33(13):4023-34 [16030353.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):979-82 [15959518.001]
  • [Cites] FEBS Lett. 1997 Jan 20;401(2-3):109-12 [9013868.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Aug 17;286(2):322-7 [11500040.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):20963-6 [10806190.001]
  • [Cites] Genomics. 1996 Sep 1;36(2):271-9 [8812453.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2958-63 [8610150.001]
  • [Cites] EMBO J. 1999 Nov 15;18(22):6455-61 [10562557.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 29;32(2):598-610 [14752048.001]
  • [Cites] Cell Cycle. 2002 Jul-Aug;1(4):245-9 [12429940.001]
  • [Cites] Mol Cell. 2004 Feb 27;13(4):611-7 [14992729.001]
  • (PMID = 16758298.001).
  • [ISSN] 1567-2379
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / BC / BC 045418; United States / NCI NIH HHS / CA / CA 102630
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Chromatin; 0 / Enzymes; 0 / SUMO-1 Protein; 0 / Saccharomyces cerevisiae Proteins; EC 2.3.2.23 / RAD6 protein, S cerevisiae; EC 2.3.2.23 / Ubiquitin-Conjugating Enzymes; EC 2.7.7.- / Rad51 Recombinase; EC 3.6.4.- / DNA Helicases; EC 6.3.2.- / ubiquitin-conjugating enzyme UBC9
  •  go-up   go-down


81. Ohishi Y, Oda Y, Kurihara S, Kaku T, Yasunaga M, Nishimura I, Okuma E, Kobayashi H, Wake N, Tsuneyoshi M: Hobnail-like cells in serous borderline tumor do not represent concomitant incipient clear cell neoplasms. Hum Pathol; 2009 Aug;40(8):1168-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hobnail-like cells, which suggest a diagnosis of clear cell carcinoma, are also focally observed in serous borderline tumor of the ovary, causing diagnostic confusion.
  • First, we carefully reviewed hematoxylin and eosin slides taken from 115 ovarian tumors diagnosed as clear cell carcinoma (73 cases), mixed adenocarcinoma containing clear cell carcinoma (5 cases), and serous borderline tumor (37 cases) to clarify the frequency of coexistence of typical clear cell carcinoma and serous borderline tumor.
  • No coexistence of clear cell carcinoma and serous borderline tumor was evident in any of the above 115 ovarian tumors.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Ovarian Neoplasms / diagnosis. Precancerous Conditions / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged. Nuclear Proteins / metabolism. Receptors, Estrogen / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19368953.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Receptors, Estrogen; 0 / WTAP protein, human
  •  go-up   go-down


82. Jin ZH, Josserand V, Razkin J, Garanger E, Boturyn D, Favrot MC, Dumy P, Coll JL: Noninvasive optical imaging of ovarian metastases using Cy5-labeled RAFT-c(-RGDfK-)4. Mol Imaging; 2006 Jul;5(3):188-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninvasive optical imaging of ovarian metastases using Cy5-labeled RAFT-c(-RGDfK-)4.
  • The aim of this study was to determine whether RAFT-c(-RGDfK-)4 combined with optical imaging could allow noninvasive detection of deep ovarian metastases.
  • Human ovarian adenocarcinoma IGROV1 cells expressing low levels of integrin alphaVbeta3 (the main receptor for the cRGD peptide) were used for in vitro and in vivo assays in combination with Cy5-labeled RAFT-c(-RGDfK-)4, cRGD, or RAFT-c(-RbetaADfK-)4.
  • [MeSH-major] Carbocyanines. Neoplasm Metastasis / radiography. Ovarian Neoplasms / radiography. Ovarian Neoplasms / secondary. Peptides, Cyclic

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16954034.001).
  • [ISSN] 1535-3508
  • [Journal-full-title] Molecular imaging
  • [ISO-abbreviation] Mol Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbocyanines; 0 / Carrier Proteins; 0 / Integrin alphaVbeta3; 0 / Peptides, Cyclic; 0 / Polymers; 0 / cyanine dye 5; 0 / cyclic arginine-glycine-aspartic acid peptide
  •  go-up   go-down


83. Goodheart MJ, Rose SL, Hattermann-Zogg M, Smith BJ, De Young BR, Buller RE: BRCA2 alteration is important in clear cell carcinoma of the ovary. Clin Genet; 2009 Aug;76(2):161-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRCA2 alteration is important in clear cell carcinoma of the ovary.
  • BRCA2 has been shown to play a significant role in hereditary ovarian carcinoma.
  • Several cases of clear cell carcinoma (CCC) of the ovary containing BRCA2 mutations have been identified.
  • We hypothesize that sequence variants of the BRCA2 gene are common in CCC of the ovary.
  • Multiple methods were utilized to detect BRCA2 genetic alterations in a cohort of 13 ovarian CCC.
  • Only one subject carried a germline sequence variation that might alter BRCA2 function despite the fact that a family history of breast, ovarian or colon cancer was common in this population.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. BRCA2 Protein / genetics. Mutation / genetics. Ovarian Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19656163.001).
  • [ISSN] 1399-0004
  • [Journal-full-title] Clinical genetics
  • [ISO-abbreviation] Clin. Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / BRCA2 Protein
  •  go-up   go-down


84. Ting AY, Kimler BF, Fabian CJ, Petroff BK: Characterization of a preclinical model of simultaneous breast and ovarian cancer progression. Carcinogenesis; 2007 Jan;28(1):130-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of a preclinical model of simultaneous breast and ovarian cancer progression.
  • Women at increased risk for breast cancer are often also at increased risk for ovarian cancer, reflecting common risk factors and intertwined etiologies for both diseases.
  • Unlike breast cancer prevention, primary ovarian cancer prevention has been impractical due to the low incidence, lack of risk and response biomarkers and difficulties in sampling ovarian tissue.
  • Challenges in the development of ovarian cancer prevention drugs, however, may be circumvented through the development of breast cancer prevention strategies that simultaneously decrease ovarian cancer.
  • In the present study, three commonly used mammary cancer carcinogen models [7,12-dimethylbenz[alpha]anthracene (DMBA), N-methyl-N-nitrosourea (MNU) and estradiol (E2)] were combined with local ovarian DMBA administration to induce progression to mammary and ovarian cancer concurrently in the rat.
  • Mammary and ovarian morphologies (measured as descriptive histology and dysplasia scores) were normal in vehicle controls.
  • Mammary hyperplasia was observed in DMBA/DMBA (mammary carcinogen/ovarian carcinogen) and MNU/DMBA-treated rats; however, ovarian preneoplastic changes were seldom observed after these treatments.
  • All E2/DMBA-treated rats had mammary hyperplasia, atypia, ductal carcinoma in situ and/or invasive adenocarcinoma, while 50% also developed preneoplastic changes in the ovary (ovarian epithelial and stromal hyperplasia and inclusion cyst formation).
  • In both the mammary gland and ovary, decreased estrogen receptor alpha expression was detected, and in the mammary gland elevated Ki-67 and cyclooxygenase-2 expressions were observed.
  • This combined breast and ovarian cancer rat model (systemic E2 treatment and local ovarian DMBA) may be useful for future dual target breast and ovarian cancer prevention studies.
  • [MeSH-major] Cocarcinogenesis. Disease Models, Animal. Mammary Neoplasms, Experimental / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] 9,10-Dimethyl-1,2-benzanthracene / toxicity. Adenocarcinoma / chemically induced. Adenocarcinoma / pathology. Alkylating Agents / toxicity. Animals. Carcinogens / toxicity. Carcinoma, Intraductal, Noninfiltrating / chemically induced. Carcinoma, Intraductal, Noninfiltrating / pathology. Cell Proliferation / drug effects. Cells, Cultured. Cyclooxygenase 2 / metabolism. Disease Progression. Epithelium / drug effects. Estrogen Receptor alpha / metabolism. Estrogens / toxicity. Female. Hyperplasia / chemically induced. Hyperplasia / pathology. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Methylnitrosourea / toxicity. Precancerous Conditions. Rats. Rats, Inbred F344

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16891317.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA089019
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Carcinogens; 0 / Estrogen Receptor alpha; 0 / Estrogens; 0 / Ki-67 Antigen; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 684-93-5 / Methylnitrosourea; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


85. Ulker V, Gedikbasi A, Numanoglu C, Ozluk Y, Saygi S, Gulkilik A, Salihoglu Y: Mucinous adenocarcinoma arising in ovarian mature cystic teratoma in pregnancy. Arch Gynecol Obstet; 2009 Aug;280(2):287-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma arising in ovarian mature cystic teratoma in pregnancy.
  • We report a case of mucinous adenocarcinoma arising from mature cystic teratoma (MCT) of the ovary ascertained incidentally during pregnancy.
  • An ovarian adnexal mass was seen in a 38-year-old pregnant woman during cesarean section.
  • Oophorectomy revealed a mucinous adenocarcinoma arising from MCT with additional capsule invasion.
  • To our knowledge, this is a case of mucinous adenocarcinoma arising from MCT and the third case of malignant transformation from MCT in pregnancy in English literature.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology. Teratoma / pathology


86. Nourbakhsh M, Golestani A, Zahrai M, Modarressi MH, Malekpour Z, Karami-Tehrani F: Androgens stimulate telomerase expression, activity and phosphorylation in ovarian adenocarcinoma cells. Mol Cell Endocrinol; 2010 Dec 15;330(1-2):10-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgens stimulate telomerase expression, activity and phosphorylation in ovarian adenocarcinoma cells.
  • Androgens have been implicated in increasing ovarian cancer risk.
  • Most ovarian cancer cells have high telomerase activity which is effective in inducing ovarian carcinogenesis.
  • The purpose of this study was to investigate the effects of testosterone and androstenedione on the viability of an ovarian adenocarcinoma cell line, the activity and expression of telomerase, and the phosphorylation status of its catalytic subunit in these cells.
  • Results showed that androgens significantly increased the viability of ovarian cancer cells and that these hormones induced the expression, activity and phosphorylation of telomerase.
  • These findings might have implications for understanding the role of androgens in ovarian carcinogenesis.
  • [MeSH-major] Adenocarcinoma / enzymology. Androgens / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Ovarian Neoplasms / enzymology. Telomerase / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. ANDROSTENEDIONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20673788.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Androgens; 0 / Protein Kinase Inhibitors; 0 / RNA, Messenger; 3XMK78S47O / Testosterone; 409J2J96VR / Androstenedione; EC 2.7.1.137 / Phosphatidylinositol 3-Kinase; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


87. Huang YD, Hung YC, Yeh LS, Chiang IP, Zeng GC, Chang WC: Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma. Taiwan J Obstet Gynecol; 2006 Sep;45(3):264-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • OBJECTIVE: We report a rare case of synchronous cancer consisting of ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • Histology showed moderately to poorly differentiated endometrioid adenocarcinoma of the right ovary with extensive lymphovascular permeation, as well as paraaortic and bilateral pelvic lymph node metastases.
  • Extensive tumor thrombi were observed in the lymphovascular channels of the left ovary, bilateral tubes and uterus.
  • Endocervical adenocarcinoma, < 3 mm in depth, was also identified on the cervix.
  • The final surgical-pathologic stage of ovarian endometrioid adenocarcinoma was stage IIIc and of endocervical mucinous adenocarcinoma was stage IA1.
  • CONCLUSION: The coexistence of primary neoplasms in the ovary and cervix is rare.
  • Diagnosis should be based on histologic examination and requires appropriate treatment for both tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Carcinoma, Endometrioid / epidemiology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / epidemiology. Uterine Cervical Neoplasms / epidemiology


88. Wang KL, Yang YC, Lai JC, Tsai TH, Lin CP, Wu YT, Chen YY, Wang SC, Chen YJ: Comparison in purity and antitumor effect of brand and generic paclitaxel against human ovarian cancer cells by an in vitro experimental model. Drug Dev Ind Pharm; 2010 Oct;36(10):1253-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison in purity and antitumor effect of brand and generic paclitaxel against human ovarian cancer cells by an in vitro experimental model.
  • By assessing the IC(50), generic paclitaxel also exhibited a greater inhibitory activity on clonogenicity of human ovarian adenocarcinoma SKOV-3 cells.
  • DISCUSSION AND CONCLUSION: The results suggest that generic paclitaxel may possess a greater cell death inducing capacity and clonogenicity inhibitory activity against ovarian cancer cells than the original brand Taxol of the same purity.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / chemistry. Antineoplastic Agents, Phytogenic / therapeutic use. Drugs, Generic / chemistry. Drugs, Generic / therapeutic use. Ovarian Neoplasms / drug therapy. Paclitaxel / chemistry. Paclitaxel / therapeutic use
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line, Tumor. Cell Survival. Drug Screening Assays, Antitumor. Female. Humans. Mitosis / drug effects

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20818963.001).
  • [ISSN] 1520-5762
  • [Journal-full-title] Drug development and industrial pharmacy
  • [ISO-abbreviation] Drug Dev Ind Pharm
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Generic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


89. Zhang Z, Sha X, Shen A, Wang Y, Sun Z, Gu Z, Fang X: Polycation nanostructured lipid carrier, a novel nonviral vector constructed with triolein for efficient gene delivery. Biochem Biophys Res Commun; 2008 Jun 6;370(3):478-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its in vitro gene transfer properties were evaluated in the human lung adenocarcinoma cell line SPC-A1 and Chinese Hamster Ovary (CHO) cells.

  • Hazardous Substances Data Bank. TRIOLEIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18395002.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cations; 0 / enhanced green fluorescent protein; 122-32-7 / Triolein; 147336-22-9 / Green Fluorescent Proteins; 9002-98-6 / Polyethyleneimine
  •  go-up   go-down


90. Ang D, Ng KY, Tan HK, Chung AY, Yew BS, Lee VK: Ovarian carcinoma presenting with isolated contralateral inguinal lymph node metastasis: a case report. Ann Acad Med Singapore; 2007 Jun;36(6):427-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian carcinoma presenting with isolated contralateral inguinal lymph node metastasis: a case report.
  • INTRODUCTION: Ovarian carcinoma usually presents at an advanced stage with diffuse intraabdominal manifestations.
  • CLINICAL PICTURE: The only clinical abnormality was an enlarged right inguinal lymph node (3 x 2 cm), for which excision biopsy revealed metastatic adenocarcinoma.
  • A computed tomography (CT) scan showed an enlarged left ovarian lesion (9.0 x 6.4 cm).
  • Histology confirmed left ovarian adenocarcinoma, consistent with the earlier histology of the right inguinal lymph node.
  • Postoperatively, the patient received adjuvant chemotherapy for treatment of FIGO Stage IIIc ovarian carcinoma and is clinically disease free 13 months after surgery.
  • CONCLUSIONS: Ovarian cancer presenting with inguinal lymph node metastases is uncommon.
  • Ovarian cancer which manifests solely as a contralateral inguinal lymph node metastasis has not been previously reported.
  • This case illustrates a rare presentation of ovarian carcinoma, and underscores the need to consider ovarian carcinoma in the differential diagnosis of women with inguinal lymphadenopathy.
  • [MeSH-major] Adenocarcinoma / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17597969.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


91. Yadav S, van Vlerken LE, Little SR, Amiji MM: Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmacol; 2009 Mar;63(4):711-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells.
  • Upon administration in multidrug resistant SKOV3(TR) human ovarian adenocarcinoma cells, siRNA-mediated MDR-1 gene silencing was evident at 100 nM dose.
  • [MeSH-major] Drug Resistance, Multiple. Gene Silencing. Nanoparticles. Ovarian Neoplasms / therapy. P-Glycoprotein / genetics. Paclitaxel / administration & dosage. Polyesters / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18618115.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA119617
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Antineoplastic Agents, Phytogenic; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / Polyesters; 0 / RNA, Small Interfering; 0 / polyethylene oxide-polycaprolactone copolymer; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


92. Takano M, Yoshikawa T, Kato M, Aida S, Goto T, Furuya K, Kikuchi Y: Primary clear cell carcinoma of the peritoneum: report of two cases and a review of the literature. Eur J Gynaecol Oncol; 2009;30(5):575-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common neoplasms of the peritoneum are malignant mesothelioma and serous papillary adenocarcinoma.
  • Clear cell carcinoma (CCC) is mostly derived from the ovary and often associated with endometriosis.
  • The ovaries and uterine endometrium of these cases were not affected, and the tumors were diagnosed as Stage IIIc CCC of the peritoneum origin.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Antineoplastic Combined Chemotherapy Protocols. Peritoneal Neoplasms / pathology

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Gynaecol Oncol. 2010;31(1):4. Yoshokawa, T [corrected to Yoshikawa, T]
  • (PMID = 19899421.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 15
  •  go-up   go-down


93. Othumpangat S, Kashon M, Joseph P: Sodium arsenite-induced inhibition of eukaryotic translation initiation factor 4E (eIF4E) results in cytotoxicity and cell death. Mol Cell Biochem; 2005 Nov;279(1-2):123-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exposure to arsenic (As) is a risk factor for the development of diabetes, vascular diseases and cancer.
  • Exposure of four different human cell lines - HCT15 (colorectal adenocarcinoma), PLC/PR/5 (hepatocellular carcinoma), HeLa (cervical adenocarcinoma) and Chang (likely derived from HeLa cells) to sodium arsenite (NaAsO2) for time intervals up to 24 h resulted in a concentration-dependent cytotoxicity and cell death.
  • Overexpression of the eIF4E gene in the Chinese hamster ovary cell line was protective against the NaAsO2-induced cytotoxicity and cell death.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Health Perspect. 1999 Jul;107(7):593-7 [10379007.001]
  • [Cites] Cell Cycle. 2003 Jul-Aug;2(4):358-68 [12851490.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 1;172(3):225-32 [11312651.001]
  • [Cites] Mutat Res. 2003 Jan 10;534(1-2):133-43 [12504762.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3445-53 [10910055.001]
  • [Cites] Mol Cell Biol. 1988 Aug;8(8):3556-9 [3062383.001]
  • [Cites] Annu Rev Biochem. 1998;67:425-79 [9759494.001]
  • [Cites] J Cell Physiol. 2002 Jan;190(1):29-37 [11807808.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33968-75 [15178684.001]
  • [Cites] J Biol Chem. 1995 Sep 8;270(36):21176-80 [7673150.001]
  • [Cites] Oncogene. 1999 Jul 29;18(30):4326-35 [10439040.001]
  • [Cites] J Toxicol Environ Health A. 2000 Jan 28;59(2):119-34 [10653439.001]
  • [Cites] J Cell Mol Med. 2001 Jul-Sep;5(3):221-39 [12067482.001]
  • [Cites] Mutat Res. 1997 Jun;386(3):219-28 [9219560.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8960-7 [15604259.001]
  • [Cites] Eur J Biochem. 2000 Feb;267(4):1083-91 [10672017.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2000;19(3):281-6 [10983894.001]
  • [Cites] Science. 1988 Jul 1;241(4861):79-81 [3388020.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Jan 15;186(2):101-9 [12639501.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24776-80 [10811643.001]
  • [Cites] Oncogene. 2000 Jun 15;19(26):3021-31 [10871854.001]
  • [Cites] J Biol Chem. 2005 Jul 1;280(26):25162-9 [15878868.001]
  • [Cites] Mol Cell Biol. 1991 Nov;11(11):5435-45 [1922056.001]
  • [Cites] Cancer Causes Control. 1997 May;8(3):371-85 [9498900.001]
  • [Cites] Cell Death Differ. 2001 Aug;8(8):841-9 [11526437.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1296-300 [7882325.001]
  • [Cites] Br J Cancer. 1992 Nov;66(5):888-92 [1419632.001]
  • [Cites] Toxicol Lett. 2002 Jul 7;133(1):47-57 [12076509.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11414-9 [11150309.001]
  • [Cites] Environ Health Perspect. 2000 May;108(5):393-7 [10811564.001]
  • [Cites] Am J Epidemiol. 1998 Apr 1;147(7):660-9 [9554605.001]
  • [Cites] Oncogene. 2000 Mar 9;19(11):1437-47 [10723135.001]
  • [Cites] J Biol Chem. 1985 May 10;260(9):5486-92 [3988764.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7950-8 [14633726.001]
  • [Cites] Toxicol Lett. 2001 Jul 6;122(3):223-34 [11489357.001]
  • [Cites] Carcinogenesis. 1985 Oct;6(10):1421-6 [3840060.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 1998 Jul-Sep;1(3):199-241 [9644328.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8212-6 [2122455.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1065-70 [8577715.001]
  • [Cites] Anal Chem. 1999 Apr 1;71(7):1408-14 [10204040.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1990-5 [11842186.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):29111-5 [11408474.001]
  • [Cites] EMBO J. 1996 Nov 15;15(22):6269-79 [8947050.001]
  • [Cites] Mol Cell Biol. 1996 Nov;16(11):6573-81 [8887686.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(6):1656-63 [11865045.001]
  • [Cites] Nucleic Acids Res. 1989 Aug 11;17(15):5923-31 [2671936.001]
  • (PMID = 16283521.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Arsenites; 0 / Eukaryotic Initiation Factor-4E; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Sodium Compounds; 0 / Ubiquitin; 136601-57-5 / Cyclin D1; 48OVY2OC72 / sodium arsenite
  •  go-up   go-down


94. Ohtsuki S, Kamoi M, Watanabe Y, Suzuki H, Hori S, Terasaki T: Correlation of induction of ATP binding cassette transporter A5 (ABCA5) and ABCB1 mRNAs with differentiation state of human colon tumor. Biol Pharm Bull; 2007 Jun;30(6):1144-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ABCA5 and ABCA8 mRNAs were detected in spleen, testis and ovary.
  • ABCA5 mRNA was detected in poorly differentiated colon adenocarcinoma (GI-112) and undifferentiated ovarian carcinoma (GI-102), but not in normal colon.
  • In contrast, ABCC1 and ABCA2 mRNAs, but not ABCA5 or ABCB1 mRNA, were detected in well differentiated colon adenocarcinoma (CX-1).
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. Adenocarcinoma / metabolism. Colonic Neoplasms / metabolism. Organic Anion Transporters / metabolism. RNA, Messenger / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541169.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / ABCA5 protein, human; 0 / ABCB1 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family B; 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 1; 0 / DNA, Complementary; 0 / Organic Anion Transporters; 0 / RNA, Messenger
  •  go-up   go-down


95. Yamano T, Morii E, Arai I, Takada T, Kubota K, Sato M, Inoue T, Okada Y, Hara T, Aozasa K: Diagnosis of primary versus metastatic ovarian adenocarcinoma using p53 gene mutation analysis. Int J Clin Oncol; 2010 Dec;15(6):621-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of primary versus metastatic ovarian adenocarcinoma using p53 gene mutation analysis.
  • Distinguishing primary ovarian cancer from metastatic colorectal cancer is often difficult by a conventional pathological examination alone.
  • We assessed the usefulness of p53 gene mutation analysis for the differential diagnosis of ovarian adenocarcinoma.
  • A 66-year-old woman suffered multiple organ metastases, including the liver, para-aortic lymph node, and right ovary, following an operation for advanced sigmoid colon cancer.
  • She underwent ovarian resection after effective chemotherapy against the liver and para-aortic lymph node cancer.
  • Histological analysis suggested primary ovarian cancer.
  • Therefore, we applied p53 gene mutation analysis for the differential diagnosis of primary versus metastatic ovarian cancer from sigmoid colon cancer.
  • The direct sequence of the p53 gene demonstrated the same gene mutation in codon 211 (ACT to ATT) in both the sigmoid colon and ovarian cancers.
  • According to the International Agency for Research on Cancer TP53 mutation database, this type of p53 mutation in colorectal cancer and ovarian cancer is 0.13% (5/3,693) and 0% (0/1,494), respectively.
  • Therefore, we determined that the ovarian tumor was metastatic.
  • Although p53 gene mutation analysis has been applied in some cases, this modality is very useful for the differential diagnosis of primary and metastatic cancer.
  • [MeSH-major] Liver Neoplasms / genetics. Liver Neoplasms / secondary. Mutation / genetics. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adenocarcinoma / secondary. Aged. Colonic Neoplasms / diagnosis. Colonic Neoplasms / genetics. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 2006 Nov-Dec;92(6):491-5 [17260489.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):128-38 [18162780.001]
  • [Cites] Mod Pathol. 2006 Nov;19(11):1421-8 [16980943.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):19-25 [15389251.001]
  • [Cites] Obstet Gynecol. 1997 Jan;89(1):85-7 [8990444.001]
  • [Cites] Eur J Gynaecol Oncol. 2004;25(6):713-5 [15597848.001]
  • [Cites] Gynecol Oncol. 2003 May;89(2):314-7 [12713997.001]
  • [Cites] J Thorac Oncol. 2008 Aug;3(8):931-4 [18670315.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7518-28 [16172461.001]
  • [Cites] Cancer Res. 1992 Sep 15;52(18):5119-22 [1516069.001]
  • [Cites] Hum Pathol. 2002 Nov;33(11):1078-85 [12454811.001]
  • [Cites] Cancer Res. 1992 Jul 1;52(13):3674-8 [1319827.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3499-504 [10999735.001]
  • [Cites] Am J Clin Pathol. 2002 Jun;117(6):944-51 [12047147.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 17;325(3):784-91 [15541358.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1209-14 [15051767.001]
  • [Cites] Clin Colorectal Cancer. 2004 Feb;3(4):215-22 [15025793.001]
  • [Cites] Ann Surg Oncol. 1998 Dec;5(8):695-8 [9869515.001]
  • [Cites] Diagn Mol Pathol. 1993 Mar;2(1):29-35 [8287223.001]
  • (PMID = 20514505.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


96. Hopfer O, Zwahlen D, Fey MF, Aebi S: The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer; 2005 Sep 19;93(6):709-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Notch pathway in ovarian carcinomas and adenomas.
  • Elements of the Notch pathway regulate differentiation; we investigated the expression of such elements in epithelial ovarian tumours.
  • A total of 32 ovarian tumour samples (17 adenocarcinomas, three borderline tumours, 12 adenomas), two human ovarian cancer (A2780, OVCAR3), and one ovarian surface (IOSE 144) cell lines were analysed.
  • Quantitative PCR revealed decreased Notch 1 mRNA in ovarian adenocarcinomas compared with adenomas.
  • HES1 protein was strongly expressed in 18/19 ovarian cancers and borderline tumours but not in adenomas.
  • Thus, Notch pathway elements are expressed in ovarian epithelial tumours and some of them are differentially expressed between adenomas and carcinomas.
  • The Notch pathway could be a target for the development of therapies for ovarian cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Membrane Proteins / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Signal Transduction
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Basic Helix-Loop-Helix Transcription Factors. Cell Proliferation. Female. Homeodomain Proteins / genetics. Homeodomain Proteins / metabolism. Humans. Middle Aged. Ovary / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Notch. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Dec;81(7):1099-102 [10584867.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6414-8 [7604005.001]
  • [Cites] Int J Cancer. 2000 Oct 1;88(1):66-70 [10962441.001]
  • [Cites] Oncogene. 2000 Aug 31;19(37):4191-8 [10980592.001]
  • [Cites] Int J Oncol. 2000 Dec;17(6):1131-9 [11078798.001]
  • [Cites] Curr Opin Mol Ther. 2000 Feb;2(1):55-65 [11249652.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3200-5 [11306509.001]
  • [Cites] Nature. 2001 May 24;411(6836):494-8 [11373684.001]
  • [Cites] EMBO J. 2001 Jul 2;20(13):3427-36 [11432830.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):5925-34 [11486031.001]
  • [Cites] Neuron. 2001 Aug 30;31(4):557-68 [11545715.001]
  • [Cites] Genes Dev. 1995 Nov 1;9(21):2609-22 [7590239.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):952-9 [8622698.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:208-18 [8747398.001]
  • [Cites] J Biol Chem. 1997 May 30;272(22):14110-4 [9162037.001]
  • [Cites] Am J Hum Genet. 1998 Mar;62(3):676-89 [9497246.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2077-88 [9528780.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2095-7 [9605750.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):214-9 [9874798.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2431-48 [10194420.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] EMBO J. 1999 May 17;18(10):2803-11 [10329626.001]
  • [Cites] J Cell Physiol. 1999 Dec;181(3):393-409 [10528225.001]
  • [Cites] Oncol Rep. 2005 Mar;13(3):375-87 [15706405.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7291-7 [11585768.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7426-9 [11606375.001]
  • [Cites] J Biol Chem. 2002 Jan 4;277(1):719-24 [11641404.001]
  • [Cites] Oncogene. 2001 Dec 20;20(58):8342-57 [11840327.001]
  • [Cites] Blood. 2002 May 1;99(9):3398-403 [11964309.001]
  • [Cites] Nat Med. 2002 Sep;8(9):979-86 [12185362.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] J Clin Invest. 2002 Oct;110(8):1165-74 [12393852.001]
  • [Cites] Biochemistry. 2003 Jan 14;42(1):137-44 [12515548.001]
  • [Cites] FASEB J. 2003 Jan;17(1):79-81 [12424225.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1777-83 [12406868.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):416-21 [12590261.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):1988-97 [12673204.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):565-76 [12842085.001]
  • [Cites] Mol Cell Biol. 2003 Sep;23(18):6694-701 [12944493.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6598-608 [14528285.001]
  • [Cites] Curr Opin Genet Dev. 2004 Feb;14(1):48-54 [15108805.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3291-300 [15161682.001]
  • [Cites] Anticancer Res. 1989 Nov-Dec;9(6):1537-47 [2697181.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Am J Pathol. 1991 Oct;139(4):777-85 [1656759.001]
  • [Cites] Blood. 1992 Feb 15;79(4):981-9 [1737106.001]
  • [Cites] Int J Cancer. 1992 Mar 12;50(5):828-33 [1544716.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9267-71 [1409633.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):4961-5 [8506342.001]
  • [Cites] Biochem J. 2000 May 1;347 Pt 3:719-24 [10769175.001]
  • (PMID = 16136053.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Homeodomain Proteins; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / Receptors, Notch; 149348-15-2 / HES1 protein, human
  • [Other-IDs] NLM/ PMC2361628
  •  go-up   go-down


97. Verbruggen MB, Verheijen RH, van de Goot FR, van Beurden M, Dorsman JC, van Diest PJ: Serous borderline tumor of the ovary presenting with cervical lymph node involvement: a report of 3 cases. Am J Surg Pathol; 2006 Jun;30(6):739-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous borderline tumor of the ovary presenting with cervical lymph node involvement: a report of 3 cases.
  • Supradiaphragmatic lymhadenopathy is extremely rare in patients with a serous borderline ovarian tumor (BOT), and clinically difficult to recognize.
  • In all the 3 cases, fine needle aspiration cytology initially indicated metastatic adenocarcinoma.
  • The primary tumor was not immediately apparent, and multiple diagnostic examinations had to be done before the definitive diagnosis of serous BOT, International Federation of Gynecology and Obstetrics stage IV could be made.
  • When fine needle aspiration cytology of such a lymph node is compatible with adenocarcinoma of unknown primary, serous BOT should be included in the differential diagnosis and pelvic examination should be performed.
  • [MeSH-major] Cystadenoma, Serous / pathology. Lymphatic Diseases / etiology. Lymphatic Metastasis / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Arm / pathology. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Inclusion Bodies / pathology. Thrombosis / etiology

  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16723852.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Sangoi AR, Soslow RA, Teng NN, Longacre TA: Ovarian clear cell carcinoma with papillary features: a potential mimic of serous tumor of low malignant potential. Am J Surg Pathol; 2008 Feb;32(2):269-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian clear cell carcinoma with papillary features: a potential mimic of serous tumor of low malignant potential.
  • The differential diagnostic problems usually associated with clear cell carcinoma (CCC) of the ovary have been well characterized and include primitive germ cell tumor, sex cord stromal tumor, and metastasis.
  • We report 13 cases of ovarian CCC with prominent papillary architecture that were initially misdiagnosed as S-LMP or low-grade serous carcinoma either on frozen section or at final diagnosis.
  • Six were associated with pelvic/ovarian endometriosis.
  • CCC with prominent papillary architecture is uncommon, but may pose a challenging differential diagnosis with S-LMP, resulting in inadequate staging and delayed treatment.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Papillary / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Endometriosis / complications. Endometriosis / pathology. Female. Fluorescent Antibody Technique, Direct. Humans. Middle Aged. Mitotic Index. Neoplasm Staging

  • Genetic Alliance. consumer health - Ovarian low malignant potential tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18223330.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


99. Nomura H, Tamada Y, Miyagi T, Suzuki A, Taira M, Suzuki N, Susumu N, Irimura T, Aoki D: Expression of NEU3 (plasma membrane-associated sialidase) in clear cell adenocarcinoma of the ovary: its relationship with T factor of pTNM classification. Oncol Res; 2006;16(6):289-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of NEU3 (plasma membrane-associated sialidase) in clear cell adenocarcinoma of the ovary: its relationship with T factor of pTNM classification.
  • Cell surface carbohydrate expression strongly influences the biological characteristics of cancer cells.
  • This study aimed to investigate sialidase expression of ovarian cancer cells and to evaluate the relationship between plasma membrane-associated sialidase (NEU3) expression and various clinicopathological factors in ovarian clear cell adenocarcinoma patients.
  • In 18 cell lines derived from human ovarian cancers (including clear cell, mucinous, and serous adenocarcinoma), sialidase mRNA expression was evaluated by RT-PCR.
  • Interestingly, NEU3 expression was detected in all clear cell adenocarcinoma cell lines.
  • In 71 patients with ovarian clear cell adenocarcinoma, treated at Keio University Hospital from February 1983 to February 2002, NEU3 expression was examined by immunohistochemical staining of surgical specimens and clinicopathological factors were reviewed.
  • This is the first report to show that NEU3 is expressed in most of ovarian clear cell adenocarcinoma.
  • And our results show that NEU3 expression is correlated with T factor (pTNM classification) in ovarian clear cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / enzymology. Adenocarcinoma, Clear Cell / pathology. Biomarkers, Tumor / metabolism. Neuraminidase / metabolism. Ovarian Neoplasms / enzymology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17476974.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 3.2.1.18 / NEU1 protein, human; EC 3.2.1.18 / NEU2 protein, human; EC 3.2.1.18 / NEU4 protein, human; EC 3.2.1.18 / Neu3 protein, human; EC 3.2.1.18 / Neuraminidase
  •  go-up   go-down


100. Ganta S, Devalapally H, Amiji M: Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. J Pharm Sci; 2010 Nov;99(11):4630-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results of this study suggest that combination of PTX and CUR, administered in nanoemulsions, could improve oral bioavailability and therapeutic efficacy in ovarian adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / pharmacokinetics. Antineoplastic Agents, Phytogenic / therapeutic use. Curcumin / pharmacology. Enzyme Inhibitors / pharmacology. Ovarian Neoplasms / drug therapy. Paclitaxel / pharmacokinetics. Paclitaxel / therapeutic use

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CURCUMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley-Liss, Inc. and the American Pharmacists Association
  • (PMID = 20845461.001).
  • [ISSN] 1520-6017
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA119617
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Emulsions; 0 / Enzyme Inhibitors; 0 / P-Glycoprotein; EC 1.14.14.1 / Cytochrome P-450 CYP3A; IT942ZTH98 / Curcumin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down






Advertisement